About us Contacts Drug interactions: 390 212
Drug search by name

Acyclovir Buccal Tablets and Mycophenolate Tablets Delayed Release

Determining the interaction of Acyclovir Buccal Tablets and Mycophenolate Tablets Delayed Release and the possibility of their joint administration.

Check result:
Acyclovir Buccal Tablets <> Mycophenolate Tablets Delayed Release
Relevance: 04.01.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Professional:

Coadministration with mycophenolic acid may increase the plasma concentrations of acyclovir. The mechanism of interaction has not been described. In 15 healthy subjects, coadministration of a single oral dose each of mycophenolate mofetil (1 gram) and acyclovir (800 mg) increased the peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and time to reach Cmax (Tmax) of acyclovir by 40%, 31% and 0.38 hour, respectively, compared to administration of acyclovir alone. In contrast, coadministration of mycophenolate mofetil with valacyclovir (2 gram) did not significantly alter acyclovir pharmacokinetics with the exception of a 0.5 hour decrease in Tmax. During coadministration with acyclovir or valacyclovir, pharmacokinetics of mycophenolic acid and its glucuronide metabolite, MPAG, were generally not significantly altered, although the AUC of MPAG decreased by 12% with valacyclovir. None of these changes are considered clinically relevant in healthy individuals. However, because both MPAG and acyclovir plasma concentrations are increased in the presence of renal impairment, the potential exists for the two drugs to compete for active tubular secretion, further increasing the concentrations of both drugs. Caution may be appropriate in patients with decreased renal function.

References
  • "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals, East Hanover, NJ.
  • "Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories, Nutley, NJ.
  • Gimenez F, Foeillet E, Bourdon O, et al. "Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects." Clin Pharmacokinet 43 (2004): 685-92
Acyclovir Buccal Tablets

Generic Name: acyclovir

Brand name: Sitavig, Zovirax

Synonyms: Acyclovir, Acyclovir (Systemic)

Mycophenolate Tablets Delayed Release

Generic Name: mycophenolic acid

Brand name: Myfortic

Synonyms: Mycophenolic acid

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.